Epidemiological Insights on Medication Concurrency and Polypharmacy in People With Multiple Sclerosis in Greece.

Q1 Nursing
International journal of MS care Pub Date : 2023-07-01 Epub Date: 2023-01-16 DOI:10.7224/1537-2073.2022-046
Christos Bakirtzis, Ioannis Nikolaidis, Marina-Kleopatra Boziki, Eleni Grigoriadou, Maria-Valeria Karakasi, Theodoros Moysiadis, Evangelia Kesidou, Georgios Papazisis, Nikolaos Grigoriadis
{"title":"Epidemiological Insights on Medication Concurrency and Polypharmacy in People With Multiple Sclerosis in Greece.","authors":"Christos Bakirtzis,&nbsp;Ioannis Nikolaidis,&nbsp;Marina-Kleopatra Boziki,&nbsp;Eleni Grigoriadou,&nbsp;Maria-Valeria Karakasi,&nbsp;Theodoros Moysiadis,&nbsp;Evangelia Kesidou,&nbsp;Georgios Papazisis,&nbsp;Nikolaos Grigoriadis","doi":"10.7224/1537-2073.2022-046","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Besides disease-modifying therapies, various pharmacologic agents are frequently prescribed to people with multiple sclerosis (MS) for symptom treatment and for comorbid conditions. The present study aims to investigate the types and frequencies of agents prescribed to people with MS in Greece using records from the nationwide digital prescription database.</p><p><strong>Methods: </strong>Prescription records for 21,218 people (65.9% women) with MS were included in the study. The criterion for study inclusion was a minimum of 3 months of continuous prescription of an agent. Identified treatments were further examined by age group.</p><p><strong>Results: </strong>Antispasticity agents (17.5%) and fampridine (14.5%) were the most regularly prescribed symptomatic medications. Antihypertensives (21.1%) and drugs for affective disorders, including antidepressants (36.1%) and anxiolytics (16.2%), were the most frequently prescribed medications for comorbid conditions. Antidepressants were prescribed at almost equally high rates among individuals older than 40 years. Hypertension was one of the leading comorbidities among the study sample, with rates rising significantly after age 40 years and plateauing after age 60 years. Polypharmacy was observed in 22.5% of the study sample, with a higher incidence among people with MS older than 60 years (46.98%).</p><p><strong>Conclusions: </strong>Agents prescribed for the treatment of disease symptoms and other medical conditions are expected to positively affect quality of life in people with MS. However, polypharmacy seems to be particularly high, especially in the aged population. The potential implications of polypharmacy in the disease course should further be explored.</p>","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"25 4","pages":"140-144"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353693/pdf/i1537-2073-25-4-140.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of MS care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7224/1537-2073.2022-046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Nursing","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Besides disease-modifying therapies, various pharmacologic agents are frequently prescribed to people with multiple sclerosis (MS) for symptom treatment and for comorbid conditions. The present study aims to investigate the types and frequencies of agents prescribed to people with MS in Greece using records from the nationwide digital prescription database.

Methods: Prescription records for 21,218 people (65.9% women) with MS were included in the study. The criterion for study inclusion was a minimum of 3 months of continuous prescription of an agent. Identified treatments were further examined by age group.

Results: Antispasticity agents (17.5%) and fampridine (14.5%) were the most regularly prescribed symptomatic medications. Antihypertensives (21.1%) and drugs for affective disorders, including antidepressants (36.1%) and anxiolytics (16.2%), were the most frequently prescribed medications for comorbid conditions. Antidepressants were prescribed at almost equally high rates among individuals older than 40 years. Hypertension was one of the leading comorbidities among the study sample, with rates rising significantly after age 40 years and plateauing after age 60 years. Polypharmacy was observed in 22.5% of the study sample, with a higher incidence among people with MS older than 60 years (46.98%).

Conclusions: Agents prescribed for the treatment of disease symptoms and other medical conditions are expected to positively affect quality of life in people with MS. However, polypharmacy seems to be particularly high, especially in the aged population. The potential implications of polypharmacy in the disease course should further be explored.

希腊多发性硬化症患者药物并发和多药治疗的流行病学见解。
背景:除了疾病改善疗法外,各种药物经常被开给多发性硬化症(MS)患者用于症状治疗和合并症。本研究旨在利用全国数字处方数据库的记录,调查希腊多发性硬化症患者处方药的类型和频率。方法:纳入21218名MS患者(女性占65.9%)的处方记录。纳入研究的标准是至少连续开药3个月。已确定的治疗方法按年龄组进行进一步检查。结果:抗痉挛药物(17.5%)和泛普定(14.5%)是最经常开具的症状药物。抗高血压药(21.1%)和治疗情感障碍的药物,包括抗抑郁药(36.1%)和抗焦虑药(16.2%),是治疗共病最常见的处方药。在40岁以上的人群中,抗抑郁药的使用率几乎同样高。高血压是研究样本中的主要合并症之一,发病率在40岁后显著上升,在60岁后趋于平稳。在22.5%的研究样本中观察到多药治疗,60岁以上多发性硬化症患者的发病率更高(46.98%)。结论:用于治疗疾病症状和其他疾病的药物有望对多发性痴呆症患者的生活质量产生积极影响。然而,多药治疗似乎特别高,尤其是在老年人群中。多药治疗在疾病过程中的潜在影响应进一步探讨。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International journal of MS care
International journal of MS care Nursing-Advanced and Specialized Nursing
CiteScore
3.00
自引率
0.00%
发文量
40
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信